Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Impact of DM/HBV Coinfection in Patients with HCV

J Gastroenterol Hepatol; ePub 2018 Jan 26; Subramaniam, et al

Hepatitis B virus (HBV) coinfection and diabetes mellitus (DM) are independent risk factors for death in patients with chronic hepatitis C infection (CHC), with antiretroviral treatment for HCV, but not HBV, a protective factor. This according to a cohort study that examined the impact of DM and HBV coinfection on clinical outcomes in CHC patients diagnosed between 2000 and 2012. The primary outcome was overall mortality. Among the details:

  • 7,149 CHC patients (mean age 56 years, 69% men) were included in the analysis; 722 (10.1%) were coinfected with HBV.
  • The prevalence of DM was similar in monoinfection and coinfection cohorts.
  • DM was identified as an independent risk factor for death and antiviral treatment for HCV as an independent protective factor against death.
  • The 5-year survival of CHC patients with monoinfection was greater than that of HBV coinfected patients (62.5% vs 57.0%).
  • The 5-year survival of patients who did or did not receive antiviral treatment for HCV was 94.7% vs 55.2%, respectively.

Citation:

Subramaniam S, Wong V W-S, Tse Y-K, et al. Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. [Published online ahead of print January 26, 2018]. J Gastroenterol Hepatol. doi:10.1111/jgh.14003.